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Summary The uPA-mediated pathway of plasminogen activation is central to cancer metastasis. Whether uPA and PAI-1 are related to local
recurrence, metastatic spread or both is not clear. We present a retrospective study of 429 primary breast cancer patients with a median follow-
up of 5.1 years, in which the levels of uPA and PAI-1 in tumour extracts were analysed by means of an enzyme-linked immunosorbent assay.
The median values of uPA and PAI-1, which were used as cut-off points, were 4.5 and 11.1 ng mg-1 protein respectively. The levels of uPA and
PAI-1 were correlated with tumour size, degree of anaplasia, steroid receptor status and number of positive nodes. Patients with high content of
either uPA or PAI-1 had increased risk of relapse and death. We demonstrated an independent ability of PAI-1 to predict distant metastasis
(relative risk 1.7, confidence limits 1.22 and 2.46) and that neither uPA nor PAI-1 provided any information regarding local recurrence.
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Cancer cells undergo the following steps during metastasis:
detachment from the primary tumour; migration; invasion of the
blood and lymphatic vessels; adhesion to and penetration of the
endothelium, allowing colonization at distant sites (Liotta et al,
1991). Tumour progression and metastasis also involve various
processes that may be called cancer cell-directed tissue remodel-
ling. Examples are angiogenesis (Folkman, 1995) and desmoplasia
(Dvorak et al, 1995).
Extracellular proteolysis has been implicated in cancer metas-
tasis for many years, with the basic idea that release ofproteolytic
enzymes from a tumour leads to breakdown of basement
membranes and extracellular matrix (ECM), thus allowing cancer
cell invasion into the surrounding normal tissue. This is true for
plasminogen activators and metalloproteinases (Dan0 et al, 1985;
Liotta et al, 1991; Mignatti and Rifkin, 1993; Andreasen et al,
1997). There are two types of plasminogen activator, the uro-
kinase-type uPA and the tissue-type tPA. Both are capable of
catalysing the formation ofthe broad spectrum proteinase plasmin
from the inactive zymogen plasminogen. There seems to be
general agreement that uPA is most important for generation of
plasmin in events involving degradation of ECM, while the
primary role of tPA is to generate plasmin for thrombolysis. In
relation to cancer metastasis, therefore, uPA is of main interest.
There are two main types of inhibitors of plasminogen activator,
PAI-1 and PAI-2. The urokinase receptor (uPAR) serves to localize
plasminogen activation to cell surfaces (Dan0 et al, 1985;
Andreasen et al, 1990, 1997; Mignatti and Rifkin, 1993).
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Recent studies have shown that the levels of uPA and PAI-I in
malignant tumours vary considerably and are related to the prog-
nosis ofthepatient (Andreasen etal, 1997). WhetheruPA andPAI-I
are related to local recurrence, metastatic spread orboth is not clear.
None of the research groups has to our knowledge looked specifi-
cally into the levels ofthese proteins in relation to the site ofrelapse.
The purpose of the present retrospective study of 429 primary
breast cancer patients was to relate tumour levels ofuPA and PAI-
1 to other prognostic factors and to the interval before local
recurrence, first distant metastasis and death.
MATERIALS AND METHODS
Patients and tumours
From August 1984 to September 1989, 502 breast cancer patients
underwent primary surgery at Odense University Hospital. All the
patients came from an unscreened population. After routine diag-
nosis, residual tumour material was available in 447 patients. The
material was stored at-80°C until the analysis for uPA and PAI-1.
Information about tumour size was missing in 18 patients. The
characteristics ofthe remaining 429 patients and their tumours are
summarized in Table 1.
Mostpatients were entered in the Danish Breast CancerCo-opera-
tive Group (DBCG) clinical trials (Andersen etal, 1981). Fifty-seven
patients were treated with breast-conserving surgery and among
those 48 had post-operative irradiation. Three hundred and seventy-
five patients were treated with a simple mastectomy and ofthose 128
had post-operative irradiation. High-risk patients (N1, T3 or T4)
were offered systemic adjuvanttherapy. Eighty-five patients received
a combination of cyclophosphamide, methotrexate and 5-fluoro-
uracil (CMF); 109 patients received endocrine therapy, and 25
received acombination ofCMFandtamoxifen. Two hundred and ten
932Prognostic value ofuPA andPAl-1 in breast cancer 933
Table 1 Patient characteristics and correlation between uPA and other variables
n(%) uPA PAI-1
medians mediana
Age (years)
<40
40-49
50-59
60-69
>70
Median 61
Range 28-92
Menopausal status
Pre
Post
32 ( 7)
76 (18)
98 (23)
100 (23)
123 (29)
137 (32)
292 (68)
Tumour size (mm)
<20
21-50
> 50
Median 25
Range 6-200
Differentiation grade
(Ductal)
11 (Ductal)
IlIl (Ductal)
Other (not ductal)
Receptor status
Positive
Negative
No. of positive nodes
0
1-3
>4
156 (36)
244 (57)
29 ( 7)
66 (15)
156 (36)
137 (32)
70 (16)
335 (78)
94 (22)
178 (41)
144 (34)
107 (25)
Invasion of lymph node capsule
No
Yes
286 (67)
143 (33)
4.4
4.0
4.3
4.7
4.8
P= 0.63b
4.3
4.6
P = 0.54b
4.1
5.0
4.1
P = 0.02b,c
4.1
4.8
5.2
2.3
p < 0.0001d
4.3
5.7
P = 0.008b
4.1
4.7
5.2
P = 0.04b
4.4
5.2
P = 0.27b
10.5
11.1
10.6
11.4
11.2
P = 0.68b
10.8
11.3
P= 0.41b
10.7
12.1
10.1
P = 0.02b,c
10.3
11.6
12.9
7.5
p < 0.0001 d
11.0
13.1
P = 0.004b
9.9
12.3
13.7
P< 0.0001b
10.3
13.9
P = 0.0009b
ang mg-1 protein. bKruskal-Wallis test. cOnly significant difference between very small tumours and medium size tumours. dOnly ductal
carcinoma was included in the Kruskal-Wallis test.
patients received no systemic treatment, 178 patients were consid-
ered to be low risk (NO, T1-2) and 32 patients were either too old or
were found to have some medical contraindications for systemic
treatment. Patients were followed atregular intervals for a maximum
of 10 years, and clinical data were obtained from patient records.
The end points for this study were:
* overall survival (OS, time from diagnosis to death from any
cause);
* recurrence free (the probability ofbeing without relapse; time
from diagnosis to the appearance of new lesion(s) in patients
with no previous evidence ofdisease, confirmed by physical
examination, biopsies and/or other relevant diagnostic
procedures) (death from cancer and death from other causes
have been censored, because almost one-third ofthe patients
were over 70 years ofage, a fact that might blur the true
picture ofrelapse);
* free oflocal recurrence (the probability ofbeing without local
recurrence, time to relapse within the local region);
* free ofdistant metastasis (the probability ofbeing free of
distant metastasis, time to metastasis outside the local region).
The result ofthe Cox regression analyses are summarized by the
relative failure (failure was classified as death, any relapse, local
relapse and distant metastasis).
The median time ofobservation was 61 months (1-128 months).
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Histopathology
Tumour size (defined as the largest invasive tumour diameter),
histological grade (Bloom and Richardson, 1957), number of axil-
lary nodes and capsule invasion were estimated at routine patho-
logical evaluation after primary surgery.
Oestrogen and progesterone receptor assays
Oestrogen receptor (ER) and progesterone receptor (PgR) were
analysed by the dextran-coated charcoal method in 371 patients
(EORTC Breast Cancer Co-operative Group, 1980; Thorpe, 1987).
The tumour was considered to be steroid receptor positive if the
value of ER or PgR was greater than 10 fmol mg-' cytosol protein.
The results were obtained from the DBCG's database. For the
remaining 58 patients, the oestrogen receptor status was estimated
semiquantitatively on paraffin-embedded tissue sections. The
technique consisted of the Pathway HRP detection system
(Pfeiffer et al, 1996). The antibody, clone ID5 (Dako), was visual-
ized by the substrate hydrogen peroxide and carbazol as the chro-
mogen. We combined the results from both methods as numerous
studies have shown concordance for ER-positive results in
between 75% and 90% ofthe cases depending on the cut-offpoint
used (Andersen et al, 1990; Esteban et al, 1994; De Mascarel et al,
1995; Alberts et al, 1996). The discordant results could be
explained by a low level ofductal cell carcinoma (DCC) positivity
or staining of non-malignant cells. The expected discordance in
this study appears to be very low as all 58 patients investigated by
immunohistochemistry had more than 50% of tumour cells posi-
tively stained.
Proteins and antibodies for uPA and PAI-1
Human uPA was purchased from Serono, Aubonne, Switzerland.
Human PAI-1, in the latent form, was prepared and converted to
active and reactive centre-cleaved forms as described by Munch et
al (1993). uPA/PAI-1 complex was prepared as described by
Nykjwr et al (1992). Human recombinant uPAR (Ploug et al, 1993)
was provided by Dr N Behrendt, Finsen Laboratory, State
University Hospital, Copenhagen, Denmark. Theprotein concentra-
tions ofthe preparations were determined by amino acid analysis.
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Figure 1 Spearman's rank correlation between uPA and PAI-l: r= 0.5675,
P < 0.001. Lines represent median values: uPA 4.5 ng mg-' protein, PAI-1
11.1 ng mg-1 protein
Three clones of murine hybridomas, producing monoclonal
anti-human uPA antibodies termed clones 2, 6 and 12 have been
described previously (Gr0ndahl-Hansen et al, 1987; Pollanen et al,
1987; Stephens et al, 1992). The epitopes for the three monoclonal
antibodies are localized in the serine proteinase domain (antibody
from clone 2) and the kringle domain (antibodies from clone 6 and
12) (Christensen et al, 1996). A rabbit polyclonal antibody was
raised against uPA from Serono. A clone of murine hybridomas
producing an anti-human PAI-i antibody, clone 2, was the one
described by Nielsen et al (1986a). The epitope for this mono-
clonal antibody is localized between amino acids 110 and 145
(Munch et al, 1991). A polyclonal rabbit antibody against PAI-I
was that described by Andreasen et al (1986). Horseradish peroxi-
dase-conjugated swine antibodies directed against rabbit anti-
bodies (P217) were purchased from Dako (Glostrup, Denmark).
Other reagents were those previously described or were ofthe best
grade commercially available (Munch et al, 1991; Nykjer et al,
1992; Christensen et al, 1996).
ELISAs for uPA and PAI-1
Tissue for analysis was taken from -80°C and homogenized
immediately in 0.1 M Tris, pH 8.1, 0.5% Triton X-100, 10 mM
EDTA and 10 ,ug ml-' aprotinin (10gl mg-' tissue) with an
Ultraturrax with a S 25 N8G head (24 000 r.p.m.) at 4°C and
centrifuged at 10000 g for 10 min to remove cell debris and
nuclei. The supernatants were analysed. The total protein concen-
tration was determined using the Bradford method. For uPA
ELISA, monoclonal anti-uPA IgG from hybridoma clones 2, 6 and
12 was used on the solid phase (2, 2 and 6 ,ug ml-' in the coating
solution respectively). For PAI-1 ELISA, monoclonal anti-PAI-I
from hybridoma clone 2 was coated on the solid phase (8 gg ml-'
in the coating solution). The second antibody layer consisted of
polyclonal rabbit anti-uPA and rabbit anti-PAI-I antibodies. As
third layer, we used peroxidase-conjugated swine antibodies
against rabbit antibodies for both ELISAs. The uPA and PAI-1
standards were the preparations described above. Other details of
the ELISAs were as described by Nielsen et al (1986b).
The uPA ELISA gave the same signal per mol ofuPA, uPA/PAI-
1 complex, uPA/uPAR complex and PAI-1/uPA/uPAR complex
(data not shown). The PAI-I ELISA gave the same signal per mol
of latent PAI-1, active PAI-1, reactive centre-cleaved PAI-1,
uPA/PAI-1 complex and PAI-1/uPA/uPAR complex (data not
shown) (Munch et al, 1991). The monoclonal anti-PAI-I antibody
from hybridoma clone 2 also reacted with vitronectin-bound PAI-I
(Andreasen, unpublished results). Internal standards added to
tumour extracts were recovered with an efficiency above 90%
(data not shown). In order to provide a further basis for compar-
ison of our results with those obtained by other ELISAs, we
analysed a reference sample designated '101094', kindly provided
by Professor T Benraad, Department of Experimental and
Chemical Endocrinology, Academic Hospital, University of
Nijmegen, The Netherlands. The aliquots of freeze-dried powder
provided (Grebenschikov et al, 1997) was reconstituted in 0.5 ml
ofa bufferof0.01 M disodium hydrogen phosphate, pH 7.4, 0.15 M
sodium chloride, 1% bovine serum albumin, 0.1S% Tween 20. Our
ELISAs gave a uPA concentration of 0.68 ± 0.06 ng ml-' (four
determinations) and a PAI-I concentration of 3.80 ± 0.17 ng ml-'
(four determinations). For comparison, Grebenschikov et al (1997)
estimated a uPA concentration of0.90 ng ml-' and a PAI-I concen-
tration of 0.91 ng ml-'. Thus, our ELISAs give a slightly lower
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value for uPA and a fourfold higher value for PAI-I than that of
Grebenschikov et al (1997).
Statistical methods
Contingency tables were analysed using the X2-test. Correlations
between uPA and PAI-1 were calculated by Spearman's rank
method. The correlation of uPA and PAI-I with other prognostic
factors was analysed using the Kruskal-Wallis test.
Probability rates of OS, being recurrence free and free of local
recurrence and distant metastasis were calculated with life-table
methods and compared using log-rank tests.
The Cox model of proportional hazards was used to study the
independent effect on survival and recurrence of each variable.
The classical prognostic factors (menopausal status, tumour size,
grade, receptor status and number ofpositive nodes) and uPA and
PAI-I were included in the multivariate analysis. Two-sided P-
values ofless than 0.05 were considered to be significant.
RESULTS
At the time ofanalysis, 201 ofthe 429 patients had relapsed (local
recurrence 47, distant metastasis 126, both 28), 180 had died, 36
were alive with recurrence and 213 were alive with no recurrence.
Table 2 Five-year survival
Variable n Recurrence Free of local Free of distant OS %(s.e.)
free % (s.e.) recurrence % metastasis % (s.e.)
(s.e.)
Menopausal status
Pre
Post
Tumour size (mm)
<20
21-50
> 50
Differentiation grade
(Ductal)
11 (Ductal)
IlIl (Ductal)
Other (not ductal)
Receptor status
Positive
Negative
No. of positive nodes
0
1-3
24
Invasion of capsule
Yes
No
uPA quartile
<2.3
2.4-4.5
4.6-7.0
> 7.0
PAI-1 quartile
<7.2
7.3-11.1
11.2-18.0
> 18.0
137
292
156
244
29
62 (4)
64 (3)
P = 0.53
81 (3)
56 (3)
33 (10)
P< 0.0001
66
156
137
70
335
94
88 (4)
61 (4)
52 (5)
69 (6)
P< 0.0001
66 (3)
55 (5)
P=0.07
178
144
107
143
286
108
111
104
106
113
103
107
106
65 (4)
57 (4)
30 (5)
P< 0.0001
40 (4)
61 (3)
P < 0.0001
71 (5)
71 (5)
58 (5)
53 (5)
P = 0.002
75 (4)
70 (5)
58 (5)
52 (5)
P< 0.0001
83 (3)
90 (2)
P=0.06
93 (2)
85 (2)
68 (9)
P= 0.001
98 (2)
87 (3)
80 (4)
88 (2)
P= 0.003
89 (2)
81 (5)
P=0.89
88 (3)
93 (2)
76 (5)
P = 0.02
86 (3)
88 (2)
P=0.45
87 (4)
85 (4)
90 (3)
85 (4)
P=0.45
88 (3)
85 (4)
87 (3)
88 (4)
P=0.73
67 (4)
67 (3)
P=0.96
83 ( 3)
59 ( 3)
45 (10)
P< 0.0001
90 (4)
65 (4)
57 (5)
68 (6)
P = 0.0001
69 (3)
61 (6)
P= 0.16
78 (3)
74 (4)
38 (5)
P< 0.0001
50 (4)
75 (3)
P< 0.0001
75 (4)
76 (4)
60 (5)
56 (5)
P = 0.001
79 (4)
75 (4)
57 (5)
54 (5)
P < 0.0001
71 (4)
61 (3)
P= 0.019
79 (3)
56 (3)
40 (9)
P< 0.0001
87 (4)
67 (4)
47 (4)
66 (6)
P < 0.0001
65 (3)
57 (5)
P= 0.12
76 (3)
68 (4)
38 (5)
P < 0.0001
48 (4)
71 (3)
P < 0.0001
75 (5)
63 (5)
65 (5)
53 (5)
P = 0.002
78 (4)
68 (5)
52 (5)
55 (5)
P < 0.0001
P-values refer to result of the long-rank test. Numbers in bold type are significant.
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The distribution of uPA and PAI-I concentrations in the 429
patients is shown in Table i. Increased concentrations ofuPA and
PAT-I were significantly correlated with increasing tumour size up
to 50 mm, increasing grade, increasing number of positive nodes
and negative steroid receptor status. PAI-1 was significantly
related to invasion ofthe lymph node capsule. Neither the uPA nor
PAI-I was related to age or menopausal status.
High levels of uPA were weakly correlated with high levels of
PAI-I (r = 0.5679, P < 0.001) (Figure 1).
Univariate prognostic analysis
The 5-year survival for classical prognostic factors and uPA and
PAI-I are listed in Table 2. Increasing size, grade, number ofposi-
tive nodes and invasion oflymph node capsules were all indicators
ofdecreased overall survival and recurrence-free probability.
uPA median
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The table shows that breast cancer patients with high content of
either uPA or PAI-I in their primary tumours had an increased risk
of relapse and death. The probability of being without recurrence
after 5 years with a uPA or PAI-I value below median was 71% and
73%, respectively, and above median 56% and 54%. The same
picture was seen foroverall survival. When specifically studying the
site ofrelapse, local or distant, uPA and PAI-I were prognostic only
forthe end point free ofdistant metastasis. The probability ofbeing
without distant metastasis after 5 years with a uPA or PAI-I value
below median was 76% and 78%, respectively, and above median
58% and 56%. By contrast, the probability of local control after 5
years was approximately 88%, regardless ofthe uPA orPAI-I value.
We found no difference in locoregional recurrence after stratifying
the patients into type ofprimary local treatment (data not shown).
In Table 2, the 5-year probabilities for the different end points,
according to uPA and PAI-1, are listed for the quartiles. Looking at
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Figure 2 Kaplan-Meier curves, with 5-year probabilities for different end points. Dotted lines present uPA or PAI-1 values below median. Solid lines present
uPA or PAI-1 above median. P-values from log-rank test
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Table 3 Multivariate analysis
Variable Death Any failure Distant metastasis
n = 429 (local or distant)
P-value RR CL 95% P-value RR CL 95% P-value RR CL 95%
Menopausal statusa 0.0013 1.7 1.24-2.40 0.96 0.55
Sizeb 0.0003 1.6 1.25-2.13 0.0001 1.8 1.33-2.38 0.0009 1.7 1.22-2.23
Gradec 0.0001 1.6 1.28-2.08 0.0155 1.4 1.06-1.78 0.0245 1.4 1.04-1.77
Receptor statusd 0.5 0.82 0.51
Lymph node statuse <0.0001 1.6 1.36-1.99 <0.0001 1.7 1.4-2.13 <0.0001 1.7 1.39-2.10
uPA medianf 0.6 0.17 0.19
PAI-1 mediang 0.0014 1.6 1.20-2.22 0.005 1.6 1.15-2.25 0.0015 1.7 1.22-2.46
aScore: 1, premenopausal; 2, post-menopausal. bScore: 1, < 20 mm; 2, 21-50 mm; 3, > 50 mm. cScore: 1, grade l; 3, grade III; 2, all others (grade 11 and
other than ductal carcinoma). dScore: 1, positive for either oestrogen and/or progesterone; 2, negative for both. ,Score: 1, no positive nodes; 2, one to three
positive nodes; 3, 2 four positive nodes. fScore: 1, below median (4.45 ng mg-' protein); 2, above median. gScore: 1, below median (11.1 ng mg-' protein);
2, above median
Table 4 uPA and relation to different end points in multivariate analysis (No subgroup analysis included)
Independent prognostic
n' Median N+ ER+ Post- Systemic PAI-1 in relation to end point in
follow-up (%) (%) menopausal adjuvant analysis multivariate analysis
References (months) (%) therapy (%)
Any failure DM
(local + (distant Death
distant) metastasis)
Duffy et al (1990,1994) 166 68 45 58 59 69 No Yes - Yes
Janicke et al (1990,1991) 113 26 54 73 60 - Yes Yes - Yes
Janicke et al (1993) 229 30 64 56 69 min.64 Yes Yes - Yes
Foekens et al (1994a) 618 48 58 74 62 25 Yes Yes - No
Foekens et al (1994b) 587 51 56 - - 22 Yes - Yes
Spyratos et al (1992) 319 72 53 70 55 37 No No Yes
Bouchet et al (1994) 314 84 53 70 55 37 Yes No No
Present study 429 61 59 77 68 51 Yes No No No
aMaximum number included in the multivariate analysis.
Table 5 PAI-1 and relation to different end points in multivariate analysis (No subgroup analysis included)
Independent prognostic
nr Median N+ ER+ Post- Systemic uPA in relation to end point in
follow-up (%) (%) menopausal adjuvant analysis multivariate analysis
References (months) (%) therapy (%)
Any failure DM
(local + (distant Death
distant) metastasis)
Janicke et al (1990,1991) 113 26 54 73 60 - Yes Yes - No
Janicke et al (1993) 229 30 64 56 69 min.64 Yes No - No
Foekens et al (1994a) 618 48 58 74 62 25 Yes Yes - Yes
Foekens et al (1994b) 587 51 56 - - 22 Yes - Yes
Bouchet et al (1994) 314 84 53 70 55 37 Yes Yes Yes
Present study 429 61 59 77 68 51 Yes Yes Yes Yes
aMaximum number included in the multivariate analysis.
the different probabilities, it seems reasonable to divide the
patients into low- and high-risk groups according to their median
values. The Kaplan-Meier curves for all end points according to
uPA and PAI-I are illustrated in Figure 2.
In order to find out whether uPA and/or PAI-I gave any more
information than the classical factors in the node-negative group,
we looked into differently constructed low-risk subgroups: a pure
node-negative group (n = 178) and a node-negative, receptor-posi-
tive group (n = 136). We investigated whether uPA above median,
PAI-I above median, high uPA and/or high PAI-I were able to
split these low-risk groups into two significantly different 5-year
probabilities forall endpoints. ButneitheruPA norPAI-1, alone or
British Journal ofCancer(1998) 77(6), 932-940 0 CancerResearch Campaign 1998938 A Knoop etal
in combination, gave any additional information, although high
uPA and/or PAT-1 showed decreased but non-significant survival
for all end points, except for local control (data not shown). This
conclusion has of course to be taken with great caution, because
the groups are very small.
Multivariate prognostic analysis
Table 3 shows the results of the Cox multivariate regression
analysis, which used all the classical variables (menopausal status,
size, grade, receptor status, number ofpositive nodes) and uPA and
PAI-I with cut-offpoints defined by their medians. The non-ductal
carcinomas were scored together with ductal grade II carcinoma
because they had approximately the same survival.
The analysis showed that size, positive nodes, grade, post-
menopausal status and high PAI-1 were independent predictors of
OS, with a relative risk (RR) of 1.6-1.7. Size, positive nodes, grade
and high PAI-I were independent predictors of any relapse, distant
and local, with an RR between 1.4 and 1.8. When the site of
relapse was studied, size, positive nodes, grade and high PAI-I
were independent predictors of distant metastasis (RR 1.4-1.7)
Only increasing size (RR 1.9, confidence limit (CL) 1.18-3.09)
and grade (RR 1.6, CL 1.03-2.49) retained independent prognostic
information for the end point local relapse (data not shown).
Our results show that, when looking at the specific site of
relapse according to the plasminogen activator system, only PAI-1,
and only with respect to predicting distant metastasis, has indepen-
dent information. The uPA retained its independent prognostic
significance for none of the end points.
DISCUSSION
Duffy et al (1988) were the first to report a shorter disease-free
survival ofbreast cancer patients with higher levels oftumour uPA
enzyme activity, and Duffy et al (1990) reported a shorter disease-
free survival for patients with higher levels oftumour uPA antigen.
Janicke et al (1991) first reported a correlation between tumour
PAI-I antigen levels and poor prognosis of breast cancer. Since
then, a number of other studies have confirmed that the uPA and
PAI-I tumour levels are correlated with poor prognosis in several
cancer types (Duffy, 1996; Andreasen et al, 1997). Results of such
studies, with more than 100 patients, are summarized in Tables 4
and 5.
Our breast cancer patient material is the second largest analysed
for uPA and PAI-1. Our results show the same general trend as the
previous studies, i.e. the correlation between uPA and PAI-I
antigen levels and poor prognosis. However, our study, which
revealed some important previously unknown results, differs in
several respects from those ofothers.
In our study, high levels of uPA and PAI-I were correlated with
increasing number of involved lymph nodes, grade, tumour size
and low content of ER or PgR. This contrasts with the majority of
the larger published studies, in which this correlation was not
found for uPA (Foucre et al, 1991; Janicke et al, 1991, 1993;
Foekens et al, 1992; Spyratos et al, 1992; Gr0ndahl-Hansen et al,
1993; Bianchi et al, 1994; Bouchet et al, 1994; Gohring et al,
1995) and only partly for PAI-I (Foucre et al, 1991; Janicke et al,
1991, 1993; Gr0ndahl-Hansen et al, 1993; Foekens et al, 1994a).
In agreement with all earlierpublished studies, we found a correla-
tion between uPA and PAI-I (Janicke et al, 1990, 1991, 1993;
Bouchet et al, 1994; Foekens et al, 1994a and b).
In contrast to our results, Table 4 shows uPA as an independent
prognostic factor for overall survival in three out of four studies,
and for recurrence-free or disease-free survival in five out of seven
studies. Although the patients of Spyratos et al (1992) and Bouchet
et al (1994) seem similar, the first study included cathepsin D and
not PAI-1, while the second study did the opposite. This is no
doubt the main explanation for the different results regarding
metastasis-free survival (MFS). Foekens et al (1994b) included
both cathepsin D and PAI-1 and found uPA to be an independent
prognostic factor for metastasis-free survival (MFS).
The picture for PAI-I is more consistent because, in all studies
(Janicke et al, 1990, 1991; Bouchet et al, 1994; Foekens et al,
1994a and b) but one, PAI-I retains its independent prognostic
significance for recurrence. The one study, which in the overall
population was non-significant (Janicke et al, 1993), showed PAI-
1 as an independent prognosticator in a subgroup analysis of the
node-negative group. We could not confirm this, even though our
node-negative group comprised more patients and had a longer
follow-up period.
The new aspect of our study was that neither uPA nor PAI-I
predicted local control and that in the multivariate analysis the
prediction of distant relapse was related to PAI-I but not to uPA.
The last was in agreement with the study from Bouchet et al
(1994) who in the multivariate analysis regarding distant relapse
found that PAI-I but not uPA retained its prognostic power. In
contrast to this, Foekens et al (1994b) found both uPA and PAI-I to
be independent predictors of distant metastasis.
There are problems in comparing the different studies because
the length of follow-up, the distribution of lymph node-positive
patients, the number of patients receiving adjuvant therapy and so
forth differ between the studies, as illustrated. Furthermore, the
multivariate analysis did not include the same variables, and all the
studies, except in part the study from Foekens et al (1994b) and
ours, used optimal cut-offpoints as the cut-offvalues in the model.
This may be the main reason for the different results obtained in
the different studies.
The median uPA and PAI-I values that we found in the tumour
extract are higher than those previously reported. We have used
Triton X-100 extracts oftumours, while several researchers use so-
called 'cytosols', originally prepared and used for steroid receptor
analysis. In our hands, the Triton X-100 extraction yields 19-fold
higher values for uPA and sixfold higher values forPAI-1 (data not
shown). Moreover, we have ensured that the antibody combination
used in the ELISA is not only specific but also gives the same
signal with all forms of the antigens that are conceivable at the
moment.
It has been claimed that uPA in detergent extracts is a stronger
prognostic parameter thancytolic uPA, andthatthis couldexplain the
fact that uPA did not retain the prognostic power in the multivariate
analysis together with PAI-I when cytolic uPA was used (Gr0ndahl-
Hansen et al, 1993). This could not be confirmed in our study.
The results from this relatively large patient group showed the
significant relationship between uPA and PAI-I and most known
prognostic factors, and confirmed other studies showing uPA and
PAI-I as giving prognostic information, although uPA did not
emerge as an independent factor. The major new findings were the
absent prognostic information of uPA and PAI-I with respect to
local control and the ability of PAI-I to independently predict
distant metastasis.
The correlation between poor prognosis and a high level ofuPA
is in agreement with the basic idea that uPA is necessary forcancer
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cell invasion. The finding that PAI-I is a strong prognostic marker
in cancer emphasizes our present lack ofin-depth understanding of
its functions in cancer. Although many new findings concerning
the cellular actions of PAI-1 have been reported recently, the
cellular mechanisms behind the correlation in the case of PAI-I is
not completely understood (Andreasen et al, 1997).
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